Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162773 · ClinicalTrials.gov registry record · Phase 2
Effect of Anti-IgE in Non-Allergic Asthma
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00162773: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT00162773 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00162773, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.
Interventions
- OTHER Placebo
- DRUG omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2005-04 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162773
The ClinicalTrials.gov registry entry for NCT00162773 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00162773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162773 about?
NCT00162773 is a clinical study titled "Effect of Anti-IgE in Non-Allergic Asthma". The purpose of this study is to find out if omalizumab is effective in treating non-allergic asthma. The US Food and Drug Administration has approved the use of omalizumab to treat moderate to severe allergic asthma.
What is the current status of trial NCT00162773?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2005-04. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00162773?
The interventions under investigation include: Placebo (OTHER), omalizumab (DRUG).
Who is sponsoring clinical trial NCT00162773?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.